Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice

被引:83
|
作者
Ganbaatar, Byambasuren [1 ]
Fukuda, Daiju [2 ]
Shinohara, Masakazu [3 ,4 ]
Yagi, Shusuke [1 ]
Kusunose, Kenya [1 ]
Yamada, Hirotsugu [5 ]
Soeki, Takeshi [1 ]
Hirata, Ken-ichi [6 ]
Sata, Masataka [1 ]
机构
[1] Tokushima Univ, Dept Cardiovasc Med, Grad Sch Biomed Sci, Tokushima 7708503, Japan
[2] Tokushima Univ, Dept Cardiodiabet Med, Grad Sch Biomed Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan
[3] Kobe Univ, Integrated Ctr Mass Spectrometry, Grad Sch Med, Kobe, Hyogo 6500017, Japan
[4] Kobe Univ, Div Epidemiol, Grad Sch Med, Kobe, Hyogo 6500017, Japan
[5] Tokushima Univ, Dept Community Med Cardiol, Grad Sch Biomed Sci, Tokushima 7708503, Japan
[6] Kobe Univ, Div Cardiovasc Med, Grad Sch Med, Kobe, Hyogo 6500017, Japan
关键词
Atherosclerosis; Inflammation; Endothelial function; SGLT2; inhibitor; Empagliflozin; PERIVASCULAR ADIPOSE-TISSUE; SGLT2; INHIBITOR; MORTALITY; ATHEROSCLEROSIS; PHENOTYPE; DISEASE; ROLES; AGES;
D O I
10.1016/j.ejphar.2020.173040
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE(-/-)) mice. Male streptozotocin (STZ) - induced diabetic ApoE(-/-) mice were treated with empagliflozin for 12 or 8 weeks. Empagliflozin lowered blood glucose (P < 0.001) and lipid levels in diabetic ApoE / mice. Empagliflozin treatment for 12 weeks significantly decreased atherosclerotic lesion size in the aortic arch (P < 0.01) along with reduction of lipid deposition (P < 0.05), macrophage accumulation (P < 0.001), and inflammatory molecule expression in plaques compared with the untreated group. Empagliflozin treatment for 8 weeks significantly ameliorated diabetes-induced endothelial dysfunction as determined by the vascular response to acetylcholine (P < 0.001). Empagliflozin reduced RNA expression of a macrophage marker, CD68, and inflammatory molecules such as MCP-1 (P < 0.05) and NADPH oxidase subunits in the aorta compared with the untreated group. Empagliflozin also reduced plasma levels of vasoconstrictive eicosanoids, prostaglandin E-2 and thromboxane B-2 (P < 0.001), which were elevated in diabetic condition. Furthermore, empagliflozin attenuated RNA expression of inflammatory molecules in perivascular adipose tissue (PVAT), suggesting the reduction of inflammation in PVAT. In in vitro studies, methylglyoxal (MGO), a precursor of AGEs, significantly increased the expression of inflammatory molecules such as MCP-1 and TNF-alpha in a murine macrophage cell line, RAW264.7. Our results indicated that empagliflozin attenuated endothelial dysfunction and atherogenesis in diabetic ApoE(-/-) mice. Reduction of vasoconstrictive eicosanoids and inflammation in the vasculature and PVAT may have a role as underlying mechanisms at least partially.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] The TP receptor antagonist S18886, but not aspirin decreases atherogenesis in diabetic apolipoprotein E-deficient mice
    Zuccollo, A
    Maitland, K
    Mastroiani, R
    Xu, SQ
    Lavielle, G
    Corda, S
    Verbeuren, TJ
    Cohen, RA
    DIABETES, 2004, 53 : A153 - A153
  • [32] Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis Independent of Its Glucose Lowering Effect in Apolipoprotein E-deficient Mice
    Kunduziayi, Aini
    Fukuda, Daiju
    Yagi, Shusuke
    Kusunose, Kenya
    Hirotsugu, Yamada
    Soeki, Takeshi
    Sata, Masataka
    CIRCULATION, 2019, 140
  • [33] Glycemic control with canagliflozin, a SGLT-2 inhibitor, attenuates atherosclerosis and endothelial dysfunction in diabetic apolipoprotein e-deficient mice
    Rahadian, A.
    Fukuda, D.
    Salim, H.
    Yagi, S.
    Kusunose, K.
    Yamada, H.
    Soeki, T.
    Sata, M.
    EUROPEAN HEART JOURNAL, 2019, 40 : 329 - 329
  • [34] Development of Apolipoprotein E-Deficient Mice
    Maeda, Nobuyo
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (09) : 1957 - 1962
  • [35] Dietary β-Carotene Rescues Vitamin A Deficiency and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice
    Harari, Ayelet
    Melnikov, Nir
    Kandel Kfir, Michal
    Kamari, Yehuda
    Mahler, Lidor
    Ben-Amotz, Ami
    Harats, Dror
    Cohen, Hofit
    Shaish, Aviv
    NUTRIENTS, 2020, 12 (06)
  • [36] Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice
    Atkinson, Robin D.
    Coenen, Kimberly R.
    Plummer, Michelle R.
    Gruen, Marnie L.
    Hasty, Alyssa H.
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2008, 294 (02): : E284 - E290
  • [37] Induction of atherogenesis in apolipoprotein E-deficient mice through superoxide production under hypoxia
    Tazawa, N
    Hayashi, T
    Mori, T
    Sohmiya, K
    Okuda, N
    Inamoto, S
    Kitaura, Y
    Nakano, D
    Ikemoto, E
    Matsumura, Y
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 271P - 271P
  • [38] Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice
    Guo, ZhongMao
    Ran, Qitao
    Roberts, L. Jackson, II
    Zhou, Lichun
    Richardson, Arlan
    Sharan, Chakradhari
    Wu, DongFan
    Yang, Hong
    FREE RADICAL BIOLOGY AND MEDICINE, 2008, 44 (03) : 343 - 352
  • [39] Accelerated atherogenesis in completely ligated common carotid artery of apolipoprotein E-deficient mice
    Chang, Zhihui
    Huangfu, Chaoji
    Grainger, Andrew T.
    Zhang, Jingang
    Guo, Qiyong
    Shi, Weibin
    ONCOTARGET, 2017, 8 (66) : 110289 - 110299
  • [40] Genetic Deletion of Stimulator of Interferon Genes Attenuates Atherogenesis in Apolipoprotein E-deficient Mice
    Pham, Phuong T.
    Fukuda, Daiju
    Sata, Masataka
    CIRCULATION, 2020, 142